Skip to content
type1.science

SiBionics GS3

SiBionics

A serious form-factor and access upgrade over GS1, with an evidence gap that the new T1D accuracy study still has to close.

A CE-marked, 14-day, calibration-free real-time CGM that is only 2.9 mm thick and sold through regional European storefronts and an Australian distributor. Its minimum age is 3 in selected countries and 18 in others. The manufacturer claims single-digit MARD, but the first registered T1D accuracy study has only just begun and no results are posted. It drives no AID system.

Available outside the USEarly evidencecgm14-dayfactory-calibratedultra-thinstandaloneOfficial site ↗

The scorecard

Accuracy55

The manufacturer claims roughly 8.7-8.83% MARD, but the new 36-person venous-reference T1D study is still recruiting and has no results. Scored on that uncertainty, not on the headline claim.[3]

Low lag40

Streams a value every five minutes, but no public ambulatory T1D data establish its lag during fast rises and falls.[1]

Interoperability12

Runs in its own phone app. No commercial pump, AID algorithm or official open-loop integration is listed.[2]

Sensor lifespan85

Fourteen-day disposable wear matches the long-wear mainstream CGMs.[1]

No calibration95

Factory-calibrated; no routine fingerstick calibration.[2]

Alerts & prediction60

Continuous Bluetooth readings and configurable high/low alerts, but no independently validated predictive-alert performance.[1]

Form factor95

The integrated sensor is 24.8 × 17.8 × 2.9 mm and 1.7 g — dramatically smaller and thinner than GS1 — with a one-piece applicator.[1]

Ketone sensing0

Glucose only; it does not measure ketones.

Access & cost74

CE-marked and directly sold across multiple non-US markets, including EU, UK and Australia listings, but absent from the US, not integrated with reimbursement or AID ecosystems in most markets, and labelled for age 3+ only in selected countries (18+ in others).[5]

Editor’s take

Thinness matters every hour you wear a sensor, and this is a genuinely small device. But a glossy 8.7% MARD printed by the seller is not interchangeable with a completed, published T1D accuracy study. Until the registered study reports, GS3 earns credit for form factor and access — not a free accuracy pass.

The full picture

The SiBionics GS3 is the smaller successor to the GS1: a disposable, factory-calibrated real-time CGM worn for up to 14 days. The redesign is not a minor trim. SiBionics lists it at 24.8 × 17.8 × 2.9 mm and 1.7 g, versus 5.3 mm thick and 3.84 g for GS1, and packages the sensor and applicator as one unit.1 It sends a new reading to the phone app over Bluetooth every five minutes and supports configurable high and low alerts.1

Available does not mean fully evidenced

GS3 is CE-marked and intended for people with type 1 or type 2 diabetes, with a minimum age of 3 in selected countries and 18 in others. It is sold through SiBionics' regional storefronts and an Australian medical-device distributor.123 It is not FDA-cleared. Exact national authorization, reimbursement and supported phone models vary, so the availability list on this page is a market-level guide, not a promise that a local health service will fund it.

The manufacturer advertises MARD around 8.7%.4 That would put the sensor in modern mainstream territory if reproduced in an appropriate T1D accuracy study. The problem is that the first ClinicalTrials.gov record designed to do exactly that was posted only on 4 August 2026. It plans to compare GS3 against venous plasma measurements over 15 days in 36 adults with T1D, but it is still recruiting and has no results.5 We therefore do not score GS3 as if the seller's number were independently established.

What it cannot do

GS3 is a standalone monitor. SiBionics does not list any pump or commercial AID system that it drives, and there is no official open-source-loop integration. That is a large practical limitation for people whose CGM is the sensing layer of an automated system. It also measures glucose only — no ketones or other context signals.

The honest position today is straightforward: GS3 looks like a meaningful wearability and access improvement over GS1, and it is a real shipping product. Its T1D accuracy, lag during rapid change, end-of-wear reliability and hypoglycemia performance remain much less transparent than those of the leading integrated sensors.

References

  1. SiBionics. Frequently Asked Questions About GS3 — 14-day wear, 24.8 × 17.8 × 2.9 mm, 1.7 g, IP38, one-piece applicator, ages 3+, continuous Bluetooth readings every five minutes and CE certification. Retrieved 8 Aug 2026. https://www.sibionicscgm.com/ga/pages/gs3-faq ↩ ↩2 ↩3

  2. SiBionics. Global Locations — official country purchasing/support routes and notice that the minimum age is 3 in selected countries and 18 in others. Retrieved 8 Aug 2026. https://www.sibionicscgm.com/pages/global-locations ↩

  3. Air Liquide Healthcare Australia. SiBionics GS3 CGM Continuous Glucose Monitoring System — current Australian product listing and local age 3+ label. Retrieved 8 Aug 2026. https://store.airliquidehealthcare.com.au/products/sibionics-gs3-cgm-continuous-glucose-monitoring-system ↩

  4. SiBionics. GS3 CGM product page — commercial availability, 14-day wear and manufacturer-claimed 8.7% MARD. The claim is not treated here as a completed independent T1D result. https://www.sibionicscgm.com/products/sibionics-gs3-cgm-continuous-glucose-monitoring-system ↩

  5. ClinicalTrials.gov. Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System Across Varying Blood Glucose Ranges (NCT07745244) — recruiting, estimated n=36 adults with T1D, China, 15-day venous-reference accuracy and safety study; posted 4 Aug 2026; no results. https://clinicaltrials.gov/study/NCT07745244 ↩

Sources

  1. [1]SiBionics GS3 frequently asked questions and specifications · manufacturer — Manufacturer states 14-day wear, 2.9 mm thickness, 1.7 g weight, IP38, a 3+ indication on this localized page, continuous Bluetooth transmission every five minutes and EU CE certification. The global page says the minimum age is 18 in some countries. Retrieved 2026-08-08.
  2. [2]SiBionics GS3 product page · manufacturer — Commercial product page claims 8.7% MARD, 14-day wear and CE conformity. The MARD is a manufacturer claim and is not used as a validated T1D trial result.
  3. [3]NCT07745244: Evaluation of GS3 CGM accuracy and safety across glucose ranges in adults with T1D · registry · 2026-08-04 — Recruiting, estimated n=36 in China; venous-reference accuracy and safety over 15 days; no results posted.
  4. [4]SiBionics GS3 sold by Air Liquide Healthcare Australia · manufacturer — Australian distributor listing confirms current sale and an Australian label for people aged 3+ with type 1 or type 2 diabetes; funding and reimbursement are not claimed.
  5. [5]SiBionics global locations and country-specific indication notice · manufacturer — Manufacturer directory links official country purchasing/support routes, including Australia, and states that the system is for ages 3+ in select countries and 18+ in others.